FDA panel recommends peginesatide for patients on dialysis

12/7/2011 | MedPage Today (free registration)

An FDA panel recommended the synthetic erythropoiesis-stimulating agent, or ESA, peginesatide as an alternative treatment for anemia in patients with chronic kidney disease undergoing dialysis. The drug, made by Affymax, works comparably to standard ESAs in increasing hemoglobin level and limiting blood transfusions in patients on dialysis, the panel said. The drug, if approved, will not be used in patients not on dialysis or patients with cancer.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ